# Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Source: https://onco.cc/trials/nct06567015/  
OnCo record `nct06567015` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STX-241 in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.

## Summary

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs is a phase 1/2 interventional study registered as NCT06567015 by Pierre Fabre Medicament, with 171 participants planned, started 2024-09-17 and due to reach its primary completion in 2027-11-20. Interventions recorded: STX-241.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06567015
- Phase: 1/2
- Setting: Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).
- Sponsor: Pierre Fabre Medicament
- Enrolled: 171

## Sources

- ClinicalTrials.gov NCT06567015: https://clinicaltrials.gov/study/NCT06567015

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06567015.json